Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared Anirban Maitra’s, Director of Perlmutter Cancer Center at NYU Langone Health, post on X, adding:
“Huge huge news!
Excited to see the full data but doubling in OS in pre-treated PDAC, HR 0.40 is unprecedented to say the least. While press-releases aren’t meant to be prematurely celebrated- we know the wave of KRAS inhibitors is coming, is here to stay and will change the face of pancreatic cancer.
What a great way to start the week! ”
Quoting Anirban Maitra‘s post:
“That Phase 3 overall survival data is in second line Pancreatic Cancer which makes the numbers even more astounding. I cannot recall any other example in pancreatic cancer when OS in a Phase 3 trial basically doubled over existing standard of care.”
Other articles featuring Udhayvir Grewal and Anirban Maitra on OncoDaily.